The Cellular Pathways of Liver Fibrosis in NASH

doi 10.20944/preprints201910.0282.v1

Full Text

Abstract

Available in

Date

Authors

Publisher

MDPI AG

Related search

Sorafenib Prevents Liver Fibrosis in a Non-Alcoholic Steatohepatitis (NASH) Rodent Model

Brazilian Journal of Medical and Biological Research
ImmunologyCell BiologyPharmacologyBiochemistryBiophysicsNeuroscienceMedicineToxicologyPhysiologyPharmaceutics
2015English

Plasma Lipidomics Distinguishes NASH and Fibrosis From Simple Fatty Liver in Children

2020English

The Roles of Gap Junctional Intercellular Communication in Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Metabolic Regulation of Hepatic PNPLA3 Expression and Severity of Liver Fibrosis in Patients With NASH

Liver International
Hepatology
2020English

C-Met Signaling Protects From Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types

Oxidative Medicine and Cellular Longevity
BiochemistryMedicineCell BiologyAging
2018English

Can Transient Elastography Be a Reliable Method for Assessing Liver Fibrosis in Non Alcoholic Steatohepatitis (NASH)?

Medical Ultrasonography
Nuclear MedicineRadiologyUltrasound TechnologyAcousticsUltrasonicsRadiologicalImaging
2013English

Complementary Vascular and Matrix Regulatory Pathways Underlie the Beneficial Mechanism of Action of Sorafenib in Liver Fibrosis

Hepatology
MedicineHepatology
2011English

Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model

American Journal of Pathology
Forensic MedicinePathology
2016English

Reversibility of Liver Fibrosis

Clinics and Research in Hepatology and Gastroenterology
HepatologyGastroenterology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy